<DOC>
	<DOC>NCT02638103</DOC>
	<brief_summary>A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous administration of TEV-48125 in adult patients with chronic migraine or episodic migraine</brief_summary>
	<brief_title>Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients Rolling Over from the Pivotal Efficacy Studies may be included in this study only if they meet all of the following criteria: Patient signs and dates the informed consent document. Patient must have completed the pivotal efficacy study without major protocol violations. Additional criteria apply, please contact the investigator for more information Patients Not Rolling Over from the Pivotal Efficacy Studies may be included in this study only if they meet all of the following criteria: Males or females aged 18 to 70 years, inclusive, with migraine onset at ≤50 years of age Patient signs and dates the informed consent document. Patient has history of migraine or clinical judgment suggests a migraine diagnosis Patient fulfills the criteria for episodic migraine (EM) or chronic migraine (CM) Total body weight between 99 and 265 lbs., inclusive All patients must be of nonchildbearing potential Patients must simultaneously use 2 forms of highly effective contraception methods Patients will remain abstinent throughout the study Patients have sexual preference that precludes the possibility of pregnancy. Female patients of childbearing potential must have a negative serum betahuman chorionic gonadotropin (βHCG) pregnancy test prior to randomization (confirmed by urine dipstick at baseline). The patient must be willing and able to comply with study restrictions, to remain at the clinic for the required duration during the study period, and to return to the clinic for the followup evaluation as specified in this protocol. Additional criteria apply, please contact the investigator for more information Patients Rolling Over from the Pivotal Efficacy Studies will be excluded from participating in this study if they meet any of the following criteria: Pregnant or nursing females Compliance with daily diary entry lower than 75% at the last month of the doubleblind treatment period of the pivotal efficacy study Patients Not Rolling Over from the Pivotal Efficacy Studies will be excluded from participating in this study if they meet any of the following criteria: Clinically significant findings at the discretion of the investigator Evidence or medical history of clinically significant psychiatric issues, including any suicide attempt in the past, or suicidal ideation with a specific plan in the past 2 years History of clinically significant cardiovascular disease or vascular ischemia Known infection or history of human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection Past or current history of cancer in the past 5 years, except for appropriately treated nonmelanoma skin carcinoma Pregnant or nursing females History of hypersensitivity reactions to injected proteins, including monoclonal antibodies h. Participation in a clinical study of a new chemical entity or a prescription medicine within 2 months before study drug administration or 5 halflives, whichever is longer Any finding considered clinically significant in the judgment of the investigator History of alcohol or drug abuse during the past 2 years, or alcohol or drug dependence during the past 5 years The patient cannot participate or successfully complete the study, in the opinion of their healthcare provider or the investigator, for any of the following reasons: mentally or legally incapacitated or unable to give consent for any reason in custody due to an administrative or a legal decision, under tutelage, or being admitted to a sanitarium or social institution unable to be contacted in case of emergency has any other condition, which, in the opinion of the investigator, makes the patient inappropriate for inclusion in the study Patient is a study center or sponsor employee who is directly involved in the study or the relative of such an employee. Additional criteria apply, please contact the investigator for more information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>